Extended Lymphadenectomy Does Not Improve DFS or OS Among Patients with Localised Muscle Invasive Bladder Cancer By Ogkologos - November 4, 2024 1974 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SWOG S1011 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer January 17, 2025 Lazertinib Demonstrates Significant Efficacy Improvement Compared with Gefitinib in the First-Line... July 17, 2023 Drug Combo JAKs Up Immunotherapy in Two Clinical Trials August 8, 2024 First Mature Estimation of Median OS for Selpercatinib in Patients with... March 12, 2025 Load more HOT NEWS Darolutamide Delays the Spread of Some Prostate Cancers 35-Year-Old Mom Has Been Living With Stage IV Breast Cancer For... No Clinically Meaningful Difference in Survival Between Nivolumab Plus Ipilimumab and... FDA Approves Dostarlimab-gxly with Chemotherapy for Endometrial Cancer
